Canadian Hemophilia Society

Recent papers from Canadian Hemophilia Society

1. Global Diagnostics of Hemophilia and Bleeding Disorders: Insights From World Federation of Hemophilia International External Quality Assessment Scheme Program 2016–2023Haemophilia · 2026
2. Normalization of Haemostasis in People with Haemophilia A: Expert Consensus on Unmet Needs and a Framework for Advancing Towards Health EquityTH Open · 2026
3. Building a gene editing lexicon: a model for rare and inherited disordersGene Therapy · 2026
4. Haemophilia Care in India: A Multicentre Cross‐Sectional Analysis From the World Bleeding Disorders Registry Benchmarking Across Global Gross National Income StrataHaemophilia · 2026
5. Implementing Shared Decision-Making in Haemophilia Care: Best Practice Recommendations From a Western European Multi-Stakeholder Delphi Process.2026
6. Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.2026
7. Clinical Spectrum, Subtype Distribution, and Treatment Outcomes in von Willebrand Disease: A Prospective Study from a Hemophilia Treatment Center in PakistanClinical and Applied Thrombosis/Hemostasis · 2026
8. Quantifying the optimal factor VIII levels to achieve patient-centric and clinician-relevant outcomes among people with hemophilia A: a SHELF elicitation studyExpert Review of Hematology · 2025
9. A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapyJournal of Thrombosis and Haemostasis · 2025
10. The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025Haemophilia · 2025
11. Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two SourcesHaemophilia · 2025
12. Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycleBlood Advances · 2025
13. Why is the uptake of gene therapy in hemophilia less than expected?Research and Practice in Thrombosis and Haemostasis · 2025
14. Inhibitor development in nonsevere hemophilia: data from the European Haemophilia Safety Surveillance (EUHASS) registryResearch and Practice in Thrombosis and Haemostasis · 2025
15. Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS RegistryHaemophilia · 2025
16. Operationalising a Haemophilia Gene Editing Lexicon for Practical UseHaemophilia · 2025
17. Adeno-associated virus-based gene therapy for hemophilia–addressing the gapsResearch and Practice in Thrombosis and Haemostasis · 2024
18. The history of women and hemophilia: a narrative review of evolving beliefs and testing practicesJournal of Thrombosis and Haemostasis · 2024
19. Five-year experience in remote diagnosis of von Willebrand disease in RussiaPediatric Hematology/Oncology and Immunopathology · 2024
20. Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand DiseaseHaemophilia · 2024